- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04847908
The Munich Adrenaline Cancer Study (MACS)
October 25, 2021 updated by: Sabine Kesting, Technical University of Munich
Changes in Metabolite Concentrations After a Single High-intensity Interval Exercise Intervention During Treatment for Childhood Cancer - A Pilot Study
Observational studies report associations between physical activity and survival in some types of adult cancer.
In addition, some exercise-induced molecules such as catecholamines (e.g., adrenaline) are known to change cancer cell signalling, proliferation and have been linked to clinical outcomes such as survival.
The aim of this study is to analyse changes in adrenaline concentration with a single high-intensity interval exercise intervention on a cycle ergometer in children and adolescents during treatment for cancer and to examine the feasibility of the study concept.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Exercise is generally recommended as an adjunct therapy for adult cancer patients as it counteracts the adverse effects of cancer and its treatment.
According to epidemiological data, exercise is also associated with a reduced risk of tumour developement and an improval of survival in some tumours.
However, the underlying mechanisms by which exercise affects tumour cells are poorly understood in adult cancer patients and mostly unknown in children.
Recent studies demonstrate anti-cancer effects of exercise-induced adrenaline through natural killer cell mobilisation and Hippo signalling.
In addition, several exercise-induced molecules such as catecholamines (e.g., adrenaline) are known to change cancer cell signalling, proliferation and have been linked to clinical outcomes such as survival.
The aim of this pilot study is the analysation of exercise-induced changes in adrenaline concentration in childhood cancer patients and to show feasibility of the study concept.
Following recruitment within the first and third cycle of chemotherapy and consent for study participation, all recruited patients perform a single high-intensity interval exercise intervention on a cycle ergometer.
Intensity of the intervals is examined both subjectively via a scale for rate of perceived exertion and objectively via changes in lactate concentration pre- and post-exercise as well as heart rate monitoring.
Blood samples are taken by trained personnel staff and prepared for processing (centrifuged, snap-frozen).
Changes in adrenaline concentration are measured with a commercial ELISA kit.
For further identification of metabolites that change with exercise, a non-biased mass spectrometry metabolomics analysis will be used.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Munich, Germany, 80804
- Kinderklinik München Schwabing, TUM School of Medicine, Department of Paediatrics and Children's Cancer Research Center, Technical University of Munich, Germany
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- newly diagnosed pediatric cancer or relapse
- aged 6-18 years
- between the first and third cycle of chemotherapy
- diagnosis and treatment at the Kinderklinik München Schwabing, Department of Paediatrics and Children's Cancer Research Centre, Technical University of Munich
- German language
- informed consent as documented by signature
Exclusion Criteria:
- Any medical contraindication with respect to a high-intensity interval exercise intervention (e.g., cardiovascular complications, comorbidities, bleeding risk, pain, infection, nausea, orthopedic impairment of the lower extremities)
- inability to follow the procedures and understand the intervention and assessment of the study, e.g., due to cognitive impairment, language problems, psychological disorders etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High-intensity interval exercise intervention
Change according to definition.
|
Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy.
Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between.
Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in adrenaline concentration
Time Frame: Pre-exercise (at rest, t0) and post-exercise (within 3 min, t1)
|
Blood samples are collected at rest pre-exercise (t0) and post-exercise (t1) via a central catheter and prepared for processing by trained personnel (centrifuged, snap-frozen).
Both at t0 and t1, 4,9ml blood are taken for adrenaline and lactate concentration (see secondary outcomes).
Serum adrenaline concentration is measured with an ELISA kit in mmol/l.
|
Pre-exercise (at rest, t0) and post-exercise (within 3 min, t1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of the study concept
Time Frame: Through study completion, on average 14 days
|
Feasibility of the study concept is examined via compliance, acceptance and safety. Detailed documentation ensures completeness of feasibility aspects. |
Through study completion, on average 14 days
|
|
Lactate concentration
Time Frame: Pre-exercise (at rest, t0) and post-exercise (within 3 min, t1)
|
Lactate concentration is analysed to examine the level of intensity of the single high-intensity interval exercise intervention.
Blood samples are collected at rest pre-exercise (t0) and post-exercise (t1), both 4,9ml, via a central catheter and prepared for processing by trained personnel.
Lactate concentration is measured with Biosen C-Line in mmol/l.
|
Pre-exercise (at rest, t0) and post-exercise (within 3 min, t1)
|
|
Heart rate
Time Frame: Pre-exercise (at rest, t0), during high-intensity interval exercise intervention and post-exercise (within 3 min, t1)
|
Heart rate monitoring is used to objectively measure the level of intensity during the single high-intensity interval exercise intervention for safety monitoring.
Heart rate levels are documented at rest pre-exercise, after every interval and post-exercise.
|
Pre-exercise (at rest, t0), during high-intensity interval exercise intervention and post-exercise (within 3 min, t1)
|
|
Physical activity before diagnosis
Time Frame: Once, pre-intervention
|
Physical activity levels are investigated using a standardised questionnaire (ActiOn) to evaluate the extent, range and intensity of physical activity shortly before the diagnosis.
This questionnaire was developed for children and adolescents during and after treatment for childhood cancer.
|
Once, pre-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Irene Teichert-von Lüttichau, PD Dr. med., TUM
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2018
Primary Completion (Actual)
May 31, 2021
Study Completion (Actual)
May 31, 2021
Study Registration Dates
First Submitted
March 31, 2021
First Submitted That Met QC Criteria
April 12, 2021
First Posted (Actual)
April 19, 2021
Study Record Updates
Last Update Posted (Actual)
October 26, 2021
Last Update Submitted That Met QC Criteria
October 25, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- TUM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Cancer
-
Dana-Farber Cancer InstituteRecruitingChildhood Cancer | Childhood Cancer SurvivorsUnited States
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorNew Zealand, Australia
-
Sydney Children's Hospitals NetworkGerman Cancer Research Center; Australian & New Zealand Children's Haematology... and other collaboratorsActive, not recruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
Children's Hospital of PhiladelphiaCompletedCancer | Childhood CancerUnited States
-
University of Colorado, DenverCompletedCancer | Childhood CancerUnited States
-
Children's Cancer Group, ChinaShanghai Children's Medical Center; Shanghai Municipal Center for Disease Prevention...Recruiting
-
Emory UniversityNational Cancer Institute (NCI)Completed
-
University of Texas Southwestern Medical CenterWithdrawn
-
University of RochesterM.D. Anderson Cancer Center; University of Colorado, Denver; University of Pittsburgh and other collaboratorsCompleted
-
St. Jude Children's Research HospitalSapere BioCompleted
Clinical Trials on Single high-intensity interval exercise intervention
-
University of Kansas Medical CenterCompletedStroke | High Intensity Interval ExerciseUnited States
-
University of GuelphCompletedPost-Exercise Hypotension | Ambulatory Blood Pressure Monitoring | High-intensity Interval ExerciseCanada
-
Laboratoire des Adaptations Métaboliques à l'Exercice...CREPS Auvergne Rhône-Alpes / VichyCompletedOverweight | PostmenopausalFrance
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
University of California, BerkeleyUniversity of San FranciscoCompleted
-
New York State Psychiatric InstituteColumbia UniversityCompleted
-
Steno Diabetes Center CopenhagenRecruiting
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
Kaohsiung Medical University Chung-Ho Memorial...Ministry of Science and Technology, TaiwanRecruiting